To identify cancer cell types that are sensitive to PTC299, a panel of 240 tumor cell lines was tested against which the concentration of compound required to reduce cell viability by 50% (CC50) was determined. Overall, the viability of 18% of cells from solid tumor(34/184) and ~57% of cells from hematologic malignancies (32/56) was reduced...

External Link:

https://ashpublications.org/blood/article/130/Supplement%201/1371/116393/PTC299-Is-a-Novel-DHODH-Inhibitor-That-Modulates